13 Feb Amiko and Sanner announce strategic partnership
Sanner and Amiko partner to develop digital solutions for true medication adherence
Bensheim/Germany, London/UK, 13 February 2018 – How can artificial intelligence, drug delivery systems and add-ons help to improve true medication adherence? By combining long-standing experience in custom-made pharmaceutical packaging, dosing and delivery systems with advanced sensor technology, Sanner and the digital health start-up Amiko are set to provide innovative answers to respiratory and other chronic diseases.
At Pharmapack Europe in Paris, Sanner and Amiko presented their cooperation for the development of smart add-on solutions for inhaled drug delivery systems. Sanner Ventures, parent company of Sanner GmbH and corporate venture capital office specializing in new technologies in the area of health and well-being, supports Amiko Digital Health Limited with a strategic investment. The funds will be used to expand Amiko’s flagship product, the Respiro platform, an innovative respiratory disease management tool.
Heading towards true medication adherence
On the operational side, Sanner GmbH, headquartered in Bensheim, Germany, will work closely with Amiko to incorporate the start-up’s patented sensor technology into custom add-on or integrated device solutions for pharmaceutical clients. “Sanner has profound experience in moisture protection solutions and custom-made primary plastic packaging, as well as in design for manufacturing and industrialization of drug delivery systems,” says Dirk Mähr, Managing Director of Sanner GmbH. “Together with Amiko’s digital Respiro Platform and unique sensor technology, we will transform our synergies into smart solutions for true medication adherence in respiratory care.”
Amiko, winner of the 1st prize at the IBM Watson AI XPRIZE annual Milestone Award 2017, is upgrading respiratory care with sensors and AI technologies.
Amiko’s Respiro platform, which has recently received the CE mark for use with certain inhaler systems, enables real-time monitoring of medication use and patient health. The patented Respiro Sense sensors, which are attached to dry powder inhalers, not only track device usage. They also facilitate true medication adherence by ensuring the medication is administered in the right way following the right technique. “Our digital health tools assist healthcare professionals and empower patients to achieve better respiratory treatment results,” says Duilio Macchi, CEO and Co-Founder of Amiko. “Together with Sanner we will advance our mission to upgrade respiratory care, improve health outcomes and reduce the costs of care for pulmonary diseases via AI-powered mobile health solutions.”
Amiko develops advanced sensor technologies and AI-powered mobile health solutions to assist healthcare professionals and empower patients to achieve better outcomes.
Founded in 2014, Amiko has headquarters in central London and ISO 13485 certified R&D laboratories in Milan. Today, Amiko serves commercial, institutional, and individual customers in Italy, Germany, France, Spain, UK and the Netherlands, and is growing to become a global provider of advanced therapeutics data and digital disease management services, empowering patients, healthcare professionals, and payers to realize a shared vision of a digital health enabled future. For more information, please visit www.amiko.io.
Based in Bensheim, Germany, the Sanner Group was founded in 1894 and is now in its fourth generation as a family-owned enterprise. Sanner develops and produces high-quality plastic packaging and drug delivery systems for pharmaceutical, medical and healthcare customers. The group gained international recognition for its desiccant know-how and moisture protection solutions. With more than 500 employees, Sanner is present all over the world, amongst others in Germany, China, India and the U.S. The company
produces over two billion plastic units each year for standard and customized packaging and drug delivery solutions. For further information, please visit www.sanner-group.com .
About Sanner Ventures
As corporate venture capital office, Sanner Ventures aims to explore new business areas and to invest in early-stage technology companies in the area of health and well-being.
Sanner Ventures is devoted to products and solutions that help protect patient health and facilitate consumer engagement. For further information, please visit www.sanner-ventures.com.